Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX Study1
Title: Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in Chinese Patients with ErbB-2+ Metastatic Breast Cancer Last modified by
CARCINOMA DELLA MAMMELLA The Aromatase Inhibitor Trials ATAC: Tamoxifen vs Anastrozole vs Combined therapy MA17 : Letrozole vs placebo after 5yr Tamoxifen IES ...
UK Guidance Algorithm on Management of Bone Loss in Early Breast Cancer ... Personal history of fragility fracture after age 50. Oral corticosteroid use of 6 months ...
These s were released by the speaker for internal use by Novartis Breast cancer recurrence: a continuing problem Tanja Cufer (Institute of Oncology, Ljubljana ...
First trial to suggest benefit for adjuvant chemo in elderly! Taxanes. Yes or ... for BC adjuvant therapy. Epidemiologic studies suggest that metformin use in ...
Over 2.5 million women living in the United States who have been diagnosed with ... paraphasing 'Bones' McCoy, Star Trek IV: The Voyage Home. Targeted Therapy ...
Advances in Adjuvant Systemic Therapy of Breast Cancer. Anne F. Schott, MD ... Comparison of Adjuvant Breast Cancer Trials of Clodronate vs. Placebo/Control ...
Cardiovascular diseases (mainly MI and cerebral stroke) are the main cause of ... In summary, an estrogen agonistic effect;'head to head' comparison suggest ...
Most common malignancy in U.S. women with 217,440 cases diagnosed in 2004. ... exposure states such as early menarche, late menopause, nulliparity and estrogen ...
ISCB 28 in Alexandroupolis Martina Mittlb ck 1. Evaluation of surrogate markers ... responsive tumours and either G1 and G2 ductal carcinoma or Gx lobular tumours ...
RUOLO DEI BISFOSFONATI NEL TRATTAMENTO DEL PAZIENTE ANZIANO CON NEOPLASIA METASTATICA ALL OSSO Daniele Santini Oncologia Medica Universit Campus Bio-Medico di Roma
IBIS-1 = International Breast Cancer Intervention Study-1. Cuzick J et al. Lancet. ... IBIS-2. N = 6000. Eligibility. Risk by family history. Postmenopausal ...
Disease-free survival (DFS) length of time after randomization during which ... contralateral carcinoma, distant metastasis, secondary carcinoma and/or death ...